Insights On Drug Development

  1. FIH: Reach Milestones Sooner With A Technology-Driven Approach 2/12/2026

    Accelerate your path to IND and FiH with AI-driven design, advanced cell line engineering, and intensified processes delivering high titers in 9–14 months.

  2. CHO K1 Cell Culture Process Intensification For Enhanced Production Of IgG mAbs 2/12/2026

    Discover how our optimized CHO K1 cell lines achieved up to an 80% increase in titer while maintaining product quality through molecule-specific process development strategies.

  3. The Science Of Cell Line Development For Biologics 2/12/2026

    Selecting and engineering the right cell line is not simply a technical milestone; it is a strategic decision that shapes cost of goods, development timelines, and the overall probability of success.

  4. Right From The Start: Smarter Developability For Stronger Formulations 2/4/2026

    Early developability assessment integrates manufacturability, QbD, flexible formulations, and CDMO support to cut risk, speed development, and enable scalable, robust drugs.

  5. Development Of A Non-Standard Protein Therapeutic 2/4/2026

    Discover how a tailored development approach transformed a complex therapeutic protein into a candidate ready for early-stage clinical trials.

  6. Viral Clearance Strategies For Monoclonal Antibodies And Proteins 1/30/2026

    Guidance on designing viral clearance studies using regulatory-aligned, risk‑based strategies, optimized assays, and real case examples for safe, efficient biologics development.

  7. Oligonucleotide Purification And Synthesis 1/27/2026

    Examine how a 21‑mer oligo was synthesized and purified through systematic resin screening, method optimization, and successful scale‑up to build reliable, high‑purity chromatography workflows.

  8. Purification And QC Of An RNA 21‑Mer Oligonucleotide Via LC‑MS 1/27/2026

    Learn how buffer choice, gradient strategy, and pretreatment steps influence recovery, purity, and resolution when purifying a native RNA oligo, with analytical confirmation and practical guidance.

  9. Scalable, Sustainable Support For Next‑Gen Primer Systems 1/27/2026

    Explore how an optimized solid‑support design enables higher synthesis scales, steadier pressures, and lower solvent use while preserving yield and purity across diverse oligonucleotide lengths.

  10. Selecting A CDMO For Custom Activated PEGs 1/27/2026

    Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.